Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders by E. Maffioletti et al.
REVIEW ARTICLE
published: 11 March 2014
doi: 10.3389/fncel.2014.00075
Micro spies from the brain to the periphery: new clues
from studies on microRNAs in neuropsychiatric disorders
Elisabetta Maffioletti1,2, Daniela Tardito3, Massimo Gennarelli 1,2 and Luisella Bocchio-Chiavetto4*
1 Genetic Unit, IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy
2 Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
3
4 Neuropsychopharmacology Unit, IRCCS Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy
Edited by:
Tommaso Pizzorusso, Università
degli Studi di Firenze, Italy
Reviewed by:
David Gurwitz, Tel Aviv University,
Israel
Kathy Keyvani, University Hospital
Essen, Germany
Declan Marcellino McLoughlin,
Trinity College Dublin, Ireland
*Correspondence:
Luisella Bocchio-Chiavetto,
Neuropsychopharmacology Unit,
IRCCS Centro S. Giovanni di Dio
Fatebenefratelli, Via Pilastroni 4,
25125 Brescia, Italy
e-mail: lbocchio@fatebenefratelli.it
microRNAs (miRNAs) are small non-coding RNAs (20–22 nucleotides) playing a major
role in post-transcriptional regulation of gene expression. miRNAs are predicted to
regulate more than 50% of all the protein-coding genes. Increasing evidence indicates
that they may play key roles in the biological pathways that regulate neurogenesis and
synaptic plasticity, as well as in neurotransmitter homeostasis in the adult brain. In
this article we review recent studies suggesting that miRNAs may be involved in the
pathophysiology of neuropsychiatric disorders and in the action of psychotropic drugs, in
particular by analyzing the contribution of genomic studies in patients’ peripheral tissues.
Alterations in miRNA expression have been observed in schizophrenia, bipolar disorder,
major depression, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric
conditions. In particular, intriguing findings concern the identification of disease-associated
miRNA signatures in peripheral tissues, or modifications in miRNA profiles induced
by drug treatments. Furthermore, genetic variations in miRNA sequences and miRNA-
related genes have been described in neuropsychiatric diseases. Overall, though still
at a preliminary stage, several lines of evidence indicate an involvement of miRNAs
in both the pathophysiology and pharmacotherapy of neuropsychiatric disorders. In this
regard, the data obtained in peripheral tissues may provide further insights into the
etiopathogenesis of several brain diseases and contribute to identify new biomarkers for
diagnostic assessment improvement and treatment personalization.
Keywords: microRNA, schizophrenia, major depression, bipolar disorder, Alzheimer disease, Parkinson disease,
genetic variation, SNP
INTRODUCTION
microRNAs (miRNAs) are a large family of conserved small
(20–22 nucleotides) non-coding RNAs, with a key role in the
post-transcriptional regulation of gene expression. In mammals,
miRNAs are predicted to control the activity of ∼50% of all
the protein-coding genes. Their discovery dates back to 1993
with the identification of lin-4, a small ribonucleotide molecule
involved in the regulation of “larva to adult switch” in C. ele-
gans (Lee et al., 1993). miRBase, the primary online repository for
all miRNA sequences, continuously upgrades the data on newly
identified miRNAs and nowadays, at its 20th release (June 2013),
it annotates 2578 human mature miRNAs and 1872 precursors
(Kozomara and Griffiths-Jones, 2014; http://www.mirbase.org)
(Figure 1).
miRNAs are transcribed in the nucleus by RNA polymerase
II to primary miRNA (pri-miRNA) transcripts, double-stranded
stem loop structures of 100–1000 nucleotides in length, then
processed to >60–70 nucleotide precursors (pre-miRNAs), by a
complex containing the RNAse-III type endonuclease Drosha and
its cofactor DGCR8, as well as other cofactors. Pre-miRNAs are
then exported in the cytoplasm by exportin-5 and cleaved in a
∼20 bp miRNA/miRNA∗ duplex by the RNase-III type enzyme
Dicer and its cofactor TRBP. In mammals, Dicer is supported
by Argonaute 2 (Ago2), a RNaseH-like endonuclease that cleaves
the 3′ arms of pre-miRNAs, thus generating mature miRNAs.
The “right” strand of the miRNA duplex is then loaded into the
RNA-induced silencing complex (RISC), whereas the other strand
(miRNA∗) is released and degraded, although in some cases both
strands can associate with RISC to target distinct sets of mRNAs
(Schwarz et al., 2003; Davis and Hata, 2009; Breving and Esquela-
Kerscher, 2010; Krol et al., 2010; O’Carroll and Schaefer, 2012)
(Figure 2).
miRNAs regulate protein synthesis post-transcriptionally by
base-pairing to target mRNAs. Generally, miRNAs inhibit pro-
tein synthesis either by repressing translation or by inducing
deadenylation and degradation of target mRNAs, but were also
reported to activate translation (Chekulaeva and Filipowicz, 2009;
Huntzinger and Izaurralde, 2011). Individual miRNAs have the
potential to target hundreds of different mRNAs, and a sin-
gle mRNA can be modulated by several different miRNAs,
thus implying a coordinate and fine-tuned regulation of protein
expression in a cell and even in particular cell compartments
(Krol et al., 2010; O’Carroll and Schaefer, 2012).
Many miRNAs are expressed in a tissue-specific or develop-
mental stage-specific manner, thereby contributing to cell type-
specific profiles of protein expression. Functional studies indicate
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FIGURE 1 | Overtime trend in the number of human microRNAs
annotated in miRBase. The number of mature human microRNAs
annotated in miRBase database (Kozomara and Griffiths-Jones, 2014;
http://www.mirbase.org) is continuously growing, starting from few dozens in
the first release (2002) to more than 2500 in the last release (version 20,
June 2013).
FIGURE 2 | Mechanisms regulating microRNA processing and release.
Pri-miRNAs are cleaved in the nucleus by Drosha (1) to generate pre-miRNAs,
then exported in the cytoplasm by Exportin-5 (2) and further cleaved by Dicer
to produce 21–23 nucleotide duplexes (3). One strand of the miRNA duplex
can either associate to the RISC complex and guide translational repression
of target mRNAs (4) or be released by the cells. In the latter case, the mature
miRNA binds to RNA-binding proteins, such as Argonaute-2 (5) or to
lipoproteins (6). Alternatively, miRNAs can be loaded in microvesicles formed
by plasma membrane blebbing (7) or in exosomes that are released in the
extracellular space upon exocytic fusion of multivesicular bodies with the
plasma membrane (8). Abbreviations: miRNA, microRNA; pre-miRNA, miRNA
precursor; pri-miRNA, primary miRNA transcript; RISC, RNA-induced
silencing complex. Figure reprinted by permission from Macmillan Publishers
Ltd: Nature Reviews Endocrinology, Guay C. and Regazzi R. Circulating
microRNAs as novel biomarkers for diabetes mellitus. 9, 513–521
(September 2013). doi: 10.1038/nrendo.2013.86.
that miRNAs participate in the regulation of almost every cel-
lular process and therefore it is not surprising that changes in
their expression or function are associated with many human
pathologies (Sayed and Abdellatif, 2011; Chan and Kocerha, 2012;
Pasquinelli, 2012), as cancer (Farazi et al., 2013; Profumo and
Gandellini, 2013) and cardiovascular diseases (Madrigal-Matute
et al., 2013; Papoutsidakis et al., 2013).
In the past few years growing evidence has supported a key
role for miRNAs in central nervous system (CNS) development
and homeostasis. It has been reported that almost 50% of all
the identified miRNAs are expressed in the human brain, with
putative target genes regulating synaptogenesis and other basic
neuronal processes (Ziats and Rennert, 2013). A role for miRNAs
in neurogenesis, neuronal differentiation and survival, as well as
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in neuroplasticity, is now well established, although further work
is needed to better clarify these aspects (Smalheiser and Lugli,
2009; Siegel et al., 2011; Olde Loohuis et al., 2012).
The unique mode of functioning of miRNAs, that is, the abil-
ity of a single miRNA to target several different mRNAs often
belonging to specific functional networks, has prompted research
toward the study of the potential involvement of miRNAs in the
pathogenesis and pharmacotherapy of neurologic and psychiatric
disorders (Kolshus et al., 2013; Tardito et al., 2013).
First evidence in post-mortem brain studies showed an overall
decrease of miRNA expression in the prefrontal cortex (PFC) of
schizophrenic (SCZ) subjects (Perkins et al., 2005, 2007; Miller
et al., 2012). Other authors described an increase in miRNA
expression in temporal regions of SCZ patients, associated to
a dysregulation of the biogenesis cofactor DGCR8, inter alia
mapped in the 22q11 Di George syndrome critical region, one
of the candidate susceptibility loci for SCZ (Beveridge et al., 2008,
2010). Elevated miRNA expression and DICER1 mRNA increase
were observed also by Santarelli et al. (2011) in dorsolateral PFC
of SCZ post-mortem brains. Furthermore, alterations in miRNA
levels were evidenced in post-mortem PFC from bipolar patients
(BD) (Kim et al., 2010; Moreau et al., 2011). Notably, most of
the differentially expressed miRNAs were downregulated in both
the SCZ and BD groups relative to controls, in line with previ-
ous results (Perkins et al., 2007), but only a few of them were
in common among the various studies. More recently, Banigan
et al. (2013) reported an increase in exosomal miRNA content in
SCZ post-mortem brains. Finally, an overall decrease in miRNA
expression was observed in PFC of depressed suicide committers,
with significant modifications of 21 miRNAs (Smalheiser et al.,
2012).
Regarding a possible involvement of miRNAs in the action
of psychotropic drugs, Zhou et al. (2009) showed that chronic
treatment with mood stabilizers induced significant modifica-
tions of miRNA expression in the rat hippocampus. The effects
of lithium on miRNA expression were confirmed also by a study
in lymphoblastoid cell lines (LCLs) from BD patients (Chen et al.,
2009). First preclinical studies on antidepressant drug effects sug-
gested a role for miR-16 in the mechanism of action of fluoxetine;
specifically, miR-16 appeared to create new serotonin sources in
the brain through the switch of noradrenergic neurons toward
a serotonergic phenotype (Baudry et al., 2010). Treatments with
fluoxetine and desipramine, two antidepressants with a differ-
ent primary mechanism of action, were reported to induce early
and time-associated miRNA modulation in rat hippocampus
(Pelizzari et al., 2012). Acute treatment with ketamine (an NMDA
receptor antagonist shown to induce a rapid and sustained antide-
pressant effect), electroconvulsive shock therapy and chronic
fluoxetine treatment were described to reverse the changes in
rat hippocampal miRNA expression induced by early life stress
(O’Connor et al., 2013). In a genome-wide miRNA investigation
conducted on LCLs screened for growth inhibition by paroxetine,
Oved et al. (2012) observed a differential expression of 6 miRNAs
in paroxetine-sensitive cells, suggesting that these miRNAs could
represent tentative SSRI response biomarkers. Finally, a modula-
tion of small subsets of miRNAs regulating metabolic pathways
was also reported after treatment with different antipsychotics,
supporting possible associations with drug side effects (Santarelli
et al., 2013).
Accumulating evidence indicates also in Alzheimer’s dis-
ease (AD) brains a dysregulation of specific miRNAs, several
of which potentially involved in the regulation of key disease
genes (see for review: Junn and Mouradian, 2012; Tan et al.,
2013). Among them, particularly interesting is the miR-29 clus-
ter, which was significantly downregulated in AD patients in
whom BACE-1 (β-amyloid cleavage enzyme 1) protein was aber-
rantly increased (Hébert et al., 2008; Nunez-Iglesias et al., 2010).
Moreover, a decrease of miR-107 in AD brains was reported,
paralleled by an increase of BACE-1 mRNA levels (Wang et al.,
2008a, 2011; Nelson and Wang, 2010). Another dysregulated
miRNA in AD brains is miR-132, which was described to be
differentially expressed also in frontotemporal lobar degenera-
tion (FTLD), together with 2 other miRNAs belonging to the
same cluster (miR-132∗ and miR-212) (Chen-Plotkin et al., 2012;
Hébert et al., 2013). Among the top target mRNAs of both
miR-132 and miR-212 there is TMEM106B, a gene linked to
FTLD by a genome-wide association study (GWAS) (Van Deerlin
et al., 2010). Concerning Parkinson’s disease (PD), decreased
brain expression levels of miR-34b and miR-34c were observed
(Miñones-Moyano et al., 2011), potentially affecting key path-
ways in PD pathogenesis, such as mitochondrial dysfunction, and
reducing DJ1 and Parkin levels. Moreover, miR-133 was identified
as deficient in PD midbrain tissue showing neuronal loss (Kim
et al., 2007). Also in vitro studies supported the involvement of
miRNAs in PD; as an example, miR-7 andmiR-153 were shown to
downregulate the expression of α-synuclein, one of the key genes
implicated in PD etiopathogenesis (Junn et al., 2009; Doxakis,
2010).
MicroRNAs AS BIOMARKERS IN PERIPHERAL TISSUES
Besides their presence in cells, miRNAs were also observed in
a highly stable, cell-free form (Cortez et al., 2011). Indeed, a
number of studies have detected miRNAs in several peripheral
biological matrices, including whole blood, plasma, serum, cere-
brospinal fluid (CSF), saliva, and others (Cogswell et al., 2008;
Mitchell et al., 2008; Park et al., 2009; Hanke et al., 2010; Zubakov
et al., 2010).
Although it is clear that miRNAs function as a mechanism
for post-transcriptional regulation, it has not been conclusively
proven whether their presence in body fluids is simply a by-
product of cell degradation or whether are they actively secreted
into the body fluids to mediate intercellular gene regulation. A
body of evidence supports the hypothesis that miRNAs can be
actively and selectively secreted; for example, miR-1246 and miR-
451 were found to be released by the breast cancer cell lineMCF-7,
but not by the non-malignant mammary epithelial breast cell line
(Pigati et al., 2010). Also in support of active secretion is the
appropriate packaging of miRNAs to facilitate circulation and to
protect them from degradation in body fluids. miRNAs in serum
are resistant to circulating ribonucleases and severe physico-
chemical conditions, such as extended storage, freeze-thawing
and extreme pH (Chen et al., 2008; Mitchell et al., 2008). As
described in Figure 2, there are three known ways by which miR-
NAs are packaged: in lipid microvesicles, such as exosomes and
Frontiers in Cellular Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 75 | 3
Maffioletti et al. Peripheral microRNA studies in neuropsychiatric disorders
apoptotic bodies; bound by RNA-binding proteins, such as nucle-
ophosmin 1 and Argonaute 2; and associated with high-density
lipoproteins (Wang et al., 2010a; Arroyo et al., 2011). Similarly to
hormones and cytokines, secreted miRNAs might serve as signal-
ing molecules of cell-to-cell communication (Valadi et al., 2007),
and their packaging also facilitates their transfer between indi-
viduals, as exemplified by the case of immune-related miRNAs in
breast milk in the first 6 months of lactation, showing that pack-
aged miRNAs could be absorbed orally and not digested (Iguchi
et al., 2010).
Recently, studies suggested that miRNAs in plasma and serum
might derive from circulating blood cells under healthy condi-
tions, but could be released from pathological tissues during an
illness (Chen et al., 2008; Fichtlscherer et al., 2010). The corre-
lation between circulating miRNAs and tissue miRNAs suggests
that miRNAs in human fluids might serve as biomarkers for
various diseases (Skog et al., 2008; Laterza et al., 2009; Zeng
et al., 2011). Some of the innate properties of miRNAs make
them highly attractive as potential biomarkers: miRNAs can be
readily detected in small volume samples using specific and sen-
sitive quantitative real-time PCR (qRT-PCR), and their levels in
plasma and serum are stable. Moreover, blood collection is a com-
mon and easy clinical procedure, and different individuals within
the same species display similar levels of circulating miRNAs.
However, a prerequisite to use circulating miRNAs as diagnos-
tic and prognostic biomarkers is the ability to quantify them in
different matrices (plasma, serum, CSF, whole blood) with an
adequate sensitivity and precision. The quality of miRNA mea-
surements with different techniques might be associated to many
variables, including those related to preanalytic variants, such
as specimen collection, RNA extraction efficiency and technical
issues related to data analysis and normalization (Kroh et al.,
2010). For example, there is a risk of cellular contamination dur-
ing CSF collection with lumbar puncture and plasma and serum
preparation; moreover, the anticoagulant used might influence
the results of the analyses, since heparin impedes a qRT-PCR
step (Boeckel et al., 2013). Furthermore, there may be an indi-
vidual variability in both the protein and lipid content in serum
and plasma specimens that could affect the efficiency of RNA
extraction. Finally, there is no consensus on suitable small RNA
reference genes that could be used as internal controls for normal-
ization in different biological fluids (Mitchell et al., 2008; Kroh
et al., 2010).
GENETIC VARIANTS IN microRNA-RELATED GENES
Two major classes of genetic variants in miRNA-related genes
have been documented: single nucleotide polymorphisms (SNPs)
and copy number variations (CNVs). SNPs are small genetic
variations in chromosomal DNA sequences in which a single
nucleotide is substituted by one of the other three nucleotides.
SNPs are the most common form of variation present in the
human genome (∼10–30 million SNPs with a frequency >1%
in the human population, occurring on average every 100–300
bases). The availability of high-throughput technologies investi-
gating the genome led to the demonstration that a large number
of genomic sequences, many of which encompass entire genes,
vary in copy number among individuals. These deletions and
duplications, referred to as CNVs, are more common in the
general population than ever imagined before. Beside population-
specific, common CNVs, there are rare, disease-causing CNVs,
which constitute an important class of genetic variability in
mendelian and multifactorial disorders. Both SNPs and CNVs in
miRNA-related genes are underrepresented compared with the
reference human genome, suggesting possible negative selection
(Duan et al., 2009; Felekkis et al., 2011; Marcinkowska et al.,
2011). In contrast, the number of miRNA target genes in poly-
morphic CNVs is higher than in non-CNV regions, suggesting
that genes integral to polymorphic CNVs are more likely to be
regulated by miRNAs, in order to counteract their expression
changes due to copy number variability of the region in which
they reside (Felekkis et al., 2011). Multiple cancer studies show
that miRNAs integral to CNVs demonstrate gain or loss at the
genomic level, and are associated with expression changes for
∼10–20% of miRNAs (Schiffman et al., 2011; Shim et al., 2012).
Genetic variants in miRNA-related genes include variations
in miRNA/pri-/pre-miRNA sequences, in miRNA biogenesis and
machinery genes, as well as in the 3′-UTR of target genes, where
mature miRNAs are bound. Therefore, these variants can affect
the transcription of pri-miRNAs, the processing and maturation
of pre-miRNAs and miRNA-mRNA interaction.
The initial demonstration that miRNA-related genetic variants
can affect disease phenotype was given by Abelson et al. (2005),
who found that a mutation in miR-189 binding site of SLITRK1
gene was associated with Tourette’s syndrome. Since then, sev-
eral studies have identified associations between polymorphisms,
mainly SNPs, influencing miRNA function and different human
disorders, going from PD tomultiple forms of cancer (Sethupathy
and Collins, 2008).
The identification of miRNA SNPs has greatly improved in
the last few years. The first efforts aimed at the selection of
these variants were conducted by Muiños-Gimeno et al. (2010)
and by Duan et al. (2009), who respectively identified 24 and
187 SNPs in miRNA/pre-miRNA sequences, employing the by
now old miRBase versions 7.1 and 13.0. More recently, thanks
to the 1000 genomes project (http://www.1000genomes.org),
many other variants have been identified; so far, more than
1000 miRNA SNP have been annotated (Han and Zheng, 2013).
Many online databases collecting miRNA SNPs, more or less
up-to-date, are available; some of them also offer informa-
tion about the association with various diseases [see for exam-
ple MicroSNiPer (http://epicenter.ie-freiburg.mpg.de/services/
microsniper/), Patrocles (http://www.patrocles.org/), Polymirts
(http://compbio.uthsc.edu/miRSNP/) and mirSNP (http://202.
38.126.151/hmdd/mirsnp/search/)].
In this narrative review we present a wide overview of recent
studies analyzing both disease alterations in miRNA expres-
sion levels in patients’ peripheral matrices and associations with
miRNA-related genetic variants.
EXPRESSION STUDIES IN HUMAN PERIPHERAL TISSUES
EXPRESSION STUDIES IN PSYCHIATRIC DISORDERS
Schizophrenia
Gardiner et al. (2012) analyzed the global miRNA expression in
peripheral blood mononuclear cells (PBMCs) from SCZ patients
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compared to healthy controls and identified an expression profile
significantly associated with SCZ; many of the differentially-
expressed miRNAs were found to be part of a large cluster on the
imprinted DLK1-DIO3 region on chromosome 14q, suggesting
a possible significant underlying genetic or epigenetic alteration
associated with this disease. To gain an appreciation of the bio-
logical implications of the disease-associated changes, the authors
also examined predicted miRNA targets, identifying many path-
ways related to neural functions, such as axon guidance, regula-
tion of the actin cytoskeleton, long-term potentiation, long-term
depression, neuroactive ligand–receptor interaction, focal adhe-
sion and neurotrophins. A similar study was conducted by Lai
et al. (2011) by evaluating miRNA expression profiles in white
blood cells (WBCs) from SCZ subjects. A 7-miRNA signature
was significantly associated with SCZ diagnosis and its clinical
characteristics, such as symptoms, neurocognitive performances
and neurophysiological functions, showing a high discriminating
accuracy. The predicted target genes for the identified miRNAs
were shown to pertain to pathways involved in nervous system
development and function, such as cyclin-dependent kinase 5
(Cdk5), Notch and dopamine receptor signaling. A candidate
miRNA approach was instead employed by Shi et al. (2012),
who measured in SCZ patients’ serum the levels of 9 miRNAs,
selected on the basis of previously published studies, since they
had been shown to be implicated in SCZ or predicted to target
SCZ-related genes. Among them, 5 were shown to be differentially
expressed. Changes in miRNA expression were also observed to
be induced by and/or implicated in effective antipsychotic treat-
ment: 2 miRNAs were downregulated after a 1-year treatment
with risperidone in plasma from first-episode SCZ patients, all
of which had achieved remission (Liu et al., 2013).
Bipolar disorder
Only one expression study was conducted on BD for one candi-
date miRNA (Rong et al., 2011). In plasma from drug-free manic
patients, miR-134 was shown to be downregulated compared to
controls; consistently, its level increased after a 4-weeks treat-
ment with different combinations of antypsychotics and/or mood
stabilizers. Both in drug-free and in medicated patients (2 and
4 weeks), miR-134 levels were negatively correlated with manic
symptoms, assessed through BRMS scores.
Major depression and anxiety
The first study on peripheral miRNA expression in drug-free
patients suffering fromMD was conducted by Bocchio-Chiavetto
et al. (2013), by evaluating the changes in global miRNA levels in
whole blood after a 12-weeks effective treatment with the antide-
pressant drug escitalopram (a SSRI). A modulation was observed
for 30miRNAs; interestingly, target gene prediction and pathways
analysis showed that these miRNAs might be implicated in sev-
eral pathways associated with brain functions, such as neuroactive
ligand–receptor interaction, axon guidance, long-term potentia-
tion and depression, supporting the hypothesis of their involve-
ment in the antidepressant mechanism. Belzeaux et al. (2012),
by means of a global analysis, reported a differential expression
of 14 miRNAs in PBMCs from non drug-free MD patients com-
pared to controls. Putative interactions between the dysregulation
in miRNAs and in mRNAs, identified through a parallel expres-
sion analysis, have been subsequently recognized. Moreover, after
an effective 8-weeks treatment with different classes of antidepres-
sant drugs, in mono- or polytherapy, a modulation was observed
for 8miRNAs. Finally, Li et al. (2013) reported in the serum of
MD patients an upregulation of 2miRNAs which had been previ-
ously described to decrease in vitro protein levels of brain-derived
neurotrophic factor (BDNF), a neurotrophin widely implicated
in MD.
Although no expression study on anxiety-related disorder in
human peripheral tissues is available, it was reported that stressful
conditions due to academic examination induce an enhancement
in blood levels of specific miRNAs, in particular miR-16, miR-
144/144∗ and miR-26b (Katsuura et al., 2012; Honda et al., 2013).
Table 1 summarizes the above-reported expression studies in
psychiatric disorders, with indication of samples, methodologies,
and main results.
EXPRESSION STUDIES IN NEUROLOGIC DISORDERS
Alzheimer’s disease and other dementias
Because of its proximity to the brain parenchyma and the free
exchange with the brain extracellular space, the biochemical com-
position of CSF provides information of the brain chemistry;
this has determined the introduction of CSF biomarker analysis
into routine clinical practice for AD (Blennow and Zetterberg,
2013). A first study conducted in CSF from AD patients identi-
fied 60 miRNAs as differentially expressed compared to healthy
individuals, both upregulated and downregulated (Cogswell et al.,
2008). Interestingly, these AD-specific miRNAs are linked to
immunity-related pathways, in particular innate immunity and
T cell activation and differentiation, which have been widely
described to be altered in AD (Boutajangout and Wisniewski,
2013; Monsonego et al., 2013). In 2012, other CSF-derived miR-
NAs were described as differentially expressed in AD (Alexandrov
et al., 2012), but contrasting results were reported by a recent
study that showed an opposite alteration of some of the same
miRNAs (Kiko et al., 2013). An interesting finding concerns the
role played by let-7b, which was found to be increased in AD
subjects. The intrathecal injection of let-7b into the CSF of mice
resulted in neurodegeneration, an effect thought to be due to
the activation of toll-like receptor (TLR) 7, since knock-out mice
lacking TLR7 were resistant to neurodegeneration (Lehmann
et al., 2012). Finally, a downregulation of miR-146 was detected
in CSF from AD patients (Müller et al., 2014).
However, CSF is a not a readily accessible tissue and this may
restrict the study sample sizes; to overcome these limitations, a
number of researches was grounded on the analysis of periph-
eral blood and its derived products, which can be more easily
obtained and potentially enable researchers to achieve larger sam-
ples. A first global investigation conducted on PBMCs led to the
identification of 4 miRNAs upregulated in AD patients (Schipper
et al., 2007). Still in PBMCs, a downregulation of miR-590-3p was
described. Intriguingly, this miRNA is strongly predicted to target
the heterogeneous nuclear ribonucleoprotein (hnRNP) A1, which
is involved in the maturation of amyloid precursor protein (APP).
The mRNA levels of hnRNPA1 were observed to be negatively
correlated with miR-590-3p levels, supporting the hypothesis that
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Table 1 | microRNA expression studies in psychiatric disorders.
Disease Sample Tissue Method Main finding Reference
Schizophrenia 112 SCZ
vs. 76
CTRL
PBMCs miRNA array Illumina
(miRBase v. 9.1),
qRT-PCR
↓ miR-31, miR-99b, miR-107, miR-134,
miR-431, miR-433, miR-487b
Gardiner et al., 2012
90 SCZ
vs. 60
CTRL
WBCs TaqMan Low Density
Array v. 1.0
↑ miR-34a, miR-449a, miR-548d, miR-564,
miR-572 and miR-652
↓ miR-432
Lai et al., 2011
115 SCZ
vs. 40
CTRL
Serum qRT-PCR ↑ let-7g, miR-181b, miR-219-2-3p, miR-1308
↓ miR-195
Shi et al., 2012
40 first-
episode
SCZ
Plasma qRT-PCR ↓ miR-365 and miR-520c-3p after a 1-year
treatment with risperidone
Liu et al., 2013
Bipolar disorder 21 BD vs.
21 CTRL
Plasma qRT-PCR In BD vs. ctrl: ↓ miR-134
↑ miR-134 after a 4-weeks treatment (different
combinations of antypsychotics and/or mood
stabilizers)
Rong et al., 2011
Major depression 10 MD Peripheral
blood
TaqMan Array
Human MicroRNA
A+B Cards Set v. 3.0
30 miRNAs differentially expressed after a
12-weeks treatment with escitalopram:
↑ let-7d, let-7e, let-7f, let-7g, miR-22*,
miR-26a, miR-26b, miR-29b-2*, miR-30d,
miR-103, miR-106b*, miR-128, miR-130b*,
miR-132, miR-140-3p, miR-183, miR-191,
miR-335, miR-361-5p, miR-374b, miR-494,
miR-500, miR-502-3p, miR-505*, miR-574-3p,
miR-589, miR-629, miR-664
↓ miR-770-5p, miR-34c-5p
Bocchio-Chiavetto
et al., 2013
9 MD vs.
9 CTRL
PBMCs TaqMan Array
Human MicroRNA
A+B Cards Set v. 3.0
In MD vs. ctrl:
↑ miR-107, miR-133a, miR-148a, miR-425-3p,
miR-494, miR-579, miR-589, miR-652, miR-941
↓ miR-200c, miR-381, miR-517b, miR-636,
miR-1243
After an 8-weeks treatment (different classes
of antidepressant drugs):
↑ miR-20b-3p, miR-133a, miR-145,
miR-409-3p, miR-410, miR-433, miR-485-3p
↓ miR-331-5p
Belzeaux et al., 2012
40 MD
vs. 40
CTRL
Serum qRT-PCR ↑ miR-132 and miR-182 Li et al., 2013
BD, bipolar disorder patients; CTRL, healthy controls; MD, major depression patients; PBMCs, peripheral blood mononuclear cells; SCZ, schizophrenia patients;
WBCs, white blood cells.
this miRNA acts as a regulator of hnRNPA1, therefore influencing
APP production (Villa et al., 2011). Another study on candidate
miRNAs, previously found to be reduced in post-mortem brain
cortices of AD patients (Geekiyanage and Chan, 2011), described
a downregulation of 4 of these (among them, miR 29a/b) in
the serum of individuals suffering from mild cognitive impair-
ment (MCI) or AD (Geekiyanage et al., 2012). This consistency
of results indicates that peripheral blood and its derivatives rep-
resent valid tissues to study miRNAs in CNS diseases, as they
could reflect brain alterations. Interestingly, miR-29a/b had been
previously shown to target BACE1/beta-secretase, whichmediates
the cleavage of APP producing β-amyloid peptide (Hébert et al.,
2008). A serum alteration of 3miRNAs was reported by an inde-
pendent study on a wide sample of AD patients and controls (105
vs. 150 subjects) (Tan et al., 2014). Sheinerman et al. (2012) iden-
tified in plasma two sets of miRNA pairs differentiating early AD
andMCI patients from healthy controls with good sensitivity and
specificity. Finally, a very recent study employed a next-generation
sequencing (NGS) technique to screen the entire miRNome in
whole peripheral blood from AD patients (Leidinger et al., 2013).
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Through this comprehensive approach, 140miRNAs were iden-
tified as differentially expressed in AD patients vs. control sub-
jects. Moreover, a panel of 12miRNAs (see Table 2) allowed to
distinguish with high diagnostic accuracy (sensitivity and speci-
ficity >92%) between AD patients and healthy controls, and
also between AD patients and patients affected by other neu-
ropsychiatric disorders, including MCI, PD, as well as SCZ, MD,
and BD.
Parkinson’s disease
A first study conducted on peripheral blood from PD patients
revealed a decrease in the expression levels of 3 miRNAs;
moreover, subjects treated with levodopa/carbidopa vs. untreated
showed higher levels of other 2miRNAs (Margis et al., 2011). A
subsequent study analyzing miRNA expression profiles in PBMCs
identified 4 differentially-expressed miRNAs. Interestingly, many
of the predicted target genes revealed an overepresentation in
pathways previously linked to PD, as well as in novel pathways
(Martins et al., 2011). Finally, through RNA-seq other miRNAs
were discovered to be differentially expressed in leukocytes from
PD patients and, consistently, after deep brain stimulation (DBS)
some of them were modulated in the opposite direction (Soreq
et al., 2013).
Table 2 summarizes the above-reported expression studies in
neurological disorders, with indication of samples, methodolo-
gies, and main results.
CLUES FROM EXPRESSION STUDIES: CONVERGING RESULTS AND
METHODOLOGICAL ISSUES
On the basis of the above-reported results on patients’ peripheral
matrices, a differential expression of a set of miRNAs emerges,
supporting a role for miRNAs as key common players for differ-
ent psychiatric and neurologic diseases. Moreover, many of these
observations converge with results obtained in cerebral tissues
from both humans and preclinical models.
miR-134 was reported to be decreased in PBMCs and plasma
respectively of SCZ and BD patients (Rong et al., 2011; Gardiner
et al., 2012); its alteration, although with an opposite direction,
was observed also in SCZ post-mortem brains (Santarelli et al.,
2011), supporting a role of this miRNA in the illness pathogen-
esis. Moreover, miR-134 was increased within a set of miRNA
associated to AD and MCI diagnosis in comparison to control
subjects (Sheinerman et al., 2012). miR-134 is a brain actively reg-
ulated miRNA mainly localized in dendritic spines, with a major
role in the regulation of synaptic proteins and neuronal plasticity,
in terms of memory and cognitive functions, through a CREB-
BDNF mediated mechanism (Gao et al., 2010a; Jimenez-Mateos
et al., 2012; Bicker et al., 2013). Moreover, miR-134 is a fine-
tuning regulator of embryonic neurodevelopment and neuronal
differentiation both in vitro and in vivo (Gaughwin et al., 2011).
miR-26a and miR-26b were found altered in peripheral
blood of MD patients during antidepressant treatment (Bocchio-
Chiavetto et al., 2013), in AD patients (Leidinger et al., 2013)
and PD patients (Margis et al., 2011), as well as in students
experiencing pre-examination stress (Honda et al., 2013). Both
miRNAs can regulate the expression of the neurotrophin BDNF,
a main player of adult brain neurogenesis and synaptic plasticity
maintenance (Caputo et al., 2011). A dysregulation of miR-26b
was observed also in SCZ and AD post-mortem brains (Perkins
et al., 2007; Absalon et al., 2013).
An increase in miR-34a peripheral blood cell content was
observed in SCZ (Lai et al., 2011) and AD patients (Schipper
et al., 2007), while antidepressant treatments were able to decrease
miR-34c-5p in the blood of MD patients (Bocchio-Chiavetto
et al., 2013). miR-34c levels were elevated in the hippocampus of
AD patients and corresponding mouse models, suggesting that
this miRNA could be a marker for the onset of cognitive dis-
turbances (Zovoilis et al., 2011). In contrast, a downregulation
of miR-34 was reported in CSF and plasma from AD patients
(Kiko et al., 2013). Moreover, an alteration of miR-34a was evi-
denced also in the PFC of SCZ post-mortem brains (Kim et al.,
2010). Basic studies indicated that Drosophila miR-34 has a
role in age-associated events, aging, and neurodegeneration (Liu
et al., 2012a). Experiments with antagomiRs revealed that target-
ing miR-34a might increase neuronal survival and reduce death
and apoptosis in a rat model of temporal lobe epilepsy (Hu
et al., 2012). Moreover, in vitro experiments showed that ectopic
expression of miR-34a downregulates the endogenous activity-
regulated, cytoskeleton-associated protein Arc, a crucial factor for
experience-dependent synaptic plasticity and long-term memory
in mammals (Wibrand et al., 2012). Finally, studies in mice mod-
els indicated a role for miR-34a in the central stress response and
suggested this miRNA as a potential target for the treatment of
stress-related disorders (Haramati et al., 2011).
miR-107 was found increased in PBMCs from MD subjects
(Belzeaux et al., 2012), but decreased in PBMCs of SCZ (Gardiner
et al., 2012) and in blood of AD patients (Leidinger et al., 2013).
Reduced levels of miR-107 were found also in AD post-mortem
brains (Nelson and Wang, 2010) and a recent study in SCZ
post-mortem brains correlated the expression levels of miR-107
with a loss in the expression of cortical muscarinic receptors
(CHRM1), observed in the 25% of patient tissues (Scarr et al.,
2013). Moreover, altered miR-107 were associated with cytoskele-
tal pathology in a transgenic mouse model of AD and with
granulin/progranulin expression regulation in vivo and in vitro,
with implications for brain disorders (Wang et al., 2008a, 2010b).
miRNAs of the let-7 family (let-7b, let-7d-3p, let-7f, let-7g)
were found dysregulated in different peripheral tissues of SCZ
patients (Shi et al., 2012), AD patients (Schipper et al., 2007;
Cogswell et al., 2008; Lehmann et al., 2012; Leidinger et al., 2013)
and modulated by antidepressant treatment (Bocchio-Chiavetto
et al., 2013), supporting their involvement in mental disorder eti-
ology and treatment. In this regard, studies in animal models
indicated a neurodegenerative effect of let-7b (Lehmann et al.,
2012) and a negative regulation of the cortical muscarinic acetyl-
choline receptor levels (M1) (Creson et al., 2011).
Other studies indicated an increase of miR-181b in serum of
SCZ patients (Shi et al., 2012) and in PBMCs of AD patients
(Schipper et al., 2007). In parallel, an upregulated expression
of this miRNA was reported in the temporal cortex of SCZ
post-mortem brains, with a concomitant downregulation of its
main neural target genes, the calcium sensor gene visinin-like
1 (VSNL1) and the ionotropic AMPA glutamate receptor sub-
unit (GRIA2), suggesting possible effects on gene expression in
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Table 2 | microRNA expression studies in neurologic disorders.
Disease Sample Tissue Method Main finding Reference
Alzheimer’s
disease
10 AD vs. 10
CTRL
CSF qRT-PCR 60 miRNAs differentially expressed; in the first positions:
↑ let-7f, miR-105, miR-125a, miR-135a, miR-138
↓ miR-10a, miR-10b, miR-126, miR-126*, miR-127
Cogswell et al., 2008
6 AD vs. 6
CTRL
CSF Fluorescent
miRNA array,
LED-Northern
dot blot
↑ miR-9, miR-125b, miR-146a, miR-155 Alexandrov et al., 2012
13 AD vs. 11
CTRL
CSF qRT-PCR ↑ let-7b Lehmann et al., 2012
20 AD vs.
22 CTRL
CSF qRT-PCR ↓ miR-146 Müller et al., 2014
10 AD vs. 10
CTRL
CSF,
plasma
qRT-PCR In CSF:
↓ miR-34a, miR-125b, miR-146a
↑ miR-29a, miR-29b
In plasma:
↓ miR-34a, miR-146a
Kiko et al., 2013
16 AD vs. 16
CTRL
PBMCs MMChip,
qRT-PCR
↑ miR-34a, miR-181b, miR-200a, let-7f Schipper et al., 2007
287 AD vs.
344 CTRL
PBMCs qRT-PCR ↓ miR-590-3p Villa et al., 2011
7 AD, 7 MCI
vs. 7 CTRL
Serum qRT-PCR ↓ miR-137, miR-181c, miR-9, miR-29a/b Geekiyanage et al., 2012
105 AD vs.
150 CTRL
Serum qRT-PCR ↓ miR-125b, miR-181c
↑ miR-9
Tan et al., 2014
20 early AD,
20 MCI vs.
20 CTRL
Plasma qRT-PCR Two sets of miRNA pairs differentiating early AD and MCI
from controls:
1) miR-128/miR-491-5p, miR-132/miR-491-5p and
mir-874/miR-491-5p
2) miR-134/miR-370, miR-323-3p/miR-370 and
miR-382/miR-370
Sheinerman et al., 2012
106 AD vs.
22 CTRL
Peripheral
blood
NGS (with
Illumina HiSeq
2000), qRT-PCR
↑ brain-miR-112, brain-miR-161, let-7d-3p, miR-5010-3p,
miR-26a-5p, miR-1285-5p, miR-151a-3p
↓ miR-103a-3p. miR-107, miR-532-5p, miR-26b-5p, let-7f-5p
Leidinger et al., 2013
Parkinson’s
disease
15 PD vs. 8
CTRL
Peripheral
blood
qRT-PCR In PD vs. ctrl:
↓ miR-1, miR-22*, miR-29
In treated with levodopa/carbidopa vs. untreated PD:
↑ miR-16-2*, miR-26a-2*
Margis et al., 2011
19 PD vs. 13
CTRL
PBMCs miRCURY LNA
microRNA Array
v. 10.0, qRT-PCR
↓ miR-116*, miR-32, miR-101
↑ miR-15
Martins et al., 2011
7 PD vs. 6
CTRL
WBCs RNA-seq (with
Applied
Biosystems
SOLiD
sequencer)
In PD vs. ctrl:
↓ miR-320a/b/c, miR-769, miR-92b, miR-16
↑ miR-199b, miR-1274b, miR-21, miR-150, miR-671,
miR-1249, miR-20a, miR-18b*, miR-378c, miR-4293
In PD after DBS:
↓ miR-4293, miR-378c, miR-18b*, miR-20a, miR-1249,
miR-424*, miR-210, miR-93
↑ miR-4317, miR-143, miR-424
Soreq et al., 2013
AD, Alzheimer’s disease patients; CSF, cerebrospinal fluid; CTRL, healthy controls; MCI, mild cognitive impairment patients; PBMCs, peripheral blood mononuclear
cells; PD, Parkinson’s disease patients; WBCs, white blood cells.
Frontiers in Cellular Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 75 | 8
Maffioletti et al. Peripheral microRNA studies in neuropsychiatric disorders
patients (Beveridge et al., 2008). A role of miR-181b in mental
pathologies could be also linked to its involvement in neuro-
protection (Peng et al., 2013) and in NMDA receptor-dependent
plasticity response in mature neurons (van Spronsen et al., 2013).
Elevated levels of miR-9 were reported in the CSF of
AD patients (Alexandrov et al., 2012), whereas lower levels
were observed in serum of patients with the same pathology
(Geekiyanage et al., 2012). miR-9 is widely expressed in the mam-
malian brain and can play a role in different neuronal functions,
ranging from early neurogenesis and differentiation to dendritic
morphogenesis and synaptic plasticity in the adult brain (Gao,
2010b), as well as in neurotoxic mechanisms, since the expres-
sion of miR-9 is downregulated by β-amyloid in hippocampal cell
cultures (Schonrock et al., 2010).
Finally, alterations in peripheral levels of miR-132 were
recently associated to MD and AD/MCI diagnosis (Sheinerman
et al., 2012; Li et al., 2013), as well as to the effects of antide-
pressant therapy (Bocchio-Chiavetto et al., 2013). These data are
consistent with the observations obtained in AD and FTLD post-
mortem brains (Hébert et al., 2013; Lau et al., 2013), confirming
in patients’ tissues the substantial role played by miR-132 in basic
mechanisms of synaptic plasticity. In particular, miR-132 is one of
the main mediators of the beneficial effects of the neurotrophin
BDNF on CNS neurons (Numakawa et al., 2011) and it is impli-
cated in brain response to stress stimuli (Shaltiel et al., 2013),
as well as in the regulation of cognitive function as learning and
memory formation (Hansen et al., 2013).
Generally speaking, miRNAs in body fluids were measured
both as single candidates using qRT-PCR methods and by the
employment of “whole-genome” approaches, through different
miRNA profiling techniques. In the reviewed studies, the most
used technologies were microarrays for the simultaneous analysis
of, at most, about 900miRNAs (Schipper et al., 2007; Alexandrov
et al., 2012; Gardiner et al., 2012) and qRT-PCR arrays which
can detect about 750miRNAs (Belzeaux et al., 2012; Bocchio-
Chiavetto et al., 2013). Microarray technologies permit a lower
cost miRNA profiling, compared to qRT-PCR arrays, but they
require the subsequent validation of the most significant results
through qRT-PCR; this can be money- and time-consuming, par-
ticularly in large study samples. Two studies (Leidinger et al.,
2013; Soreq et al., 2013) analyzedmiRNA profiles with small RNA
NGS, which virtually allows the detection of all the miRNAs and
other small RNAs expressed in a given sample. NGS techniques
were employed also in basic examinations to characterize miRNA
whole expression in different biofluids, highlighting the presence
of more than 500 and 400miRNAs, respectively in serum and CSF
of healthy subjects (Burgos et al., 2013).
It is still an open question whether and how miRNA levels
in the periphery (such as in CSF, serum, plasma, blood, lym-
phoblasts etc.) may reflect brain modifications, and this issue
generally concerns all the potential peripheral biomarkers in psy-
chiatric and neurologic disorders. A first evidence has suggested
a possible correlation between central and peripheral levels, since
miRNAs could pass through biological membranes in free-form
or into microvesicles. In this regard, tumor-specific microvesi-
cles containing miRNAs at altered levels were detected in the
serum of patients affected by glioblastomas (Skog et al., 2008)
and brain-specific miRNAs quantified in plasma were proposed
as biomarkers for brain injury in animal models (Laterza et al.,
2009). Finally the levels of miR-210, described as significantly
decreased in the blood of stroke patients, showed a correlation
between brain and blood in ischemic mice (Zeng et al., 2011).
A major reason for the lack of conclusive data might be
attributed to the low number of studies which have explored
brain-periphery correlation, also due to the difficulties in get-
ting concomitant brain and peripheral samples of the same
human subjects. This problem could be overcome by the employ-
ment of animal models; however, these studies are limited, since
the number of annotated miRNAs is widely different between
species (miRBase 20th release, June 2013: 2578 mature miRNAs
in humans, 728 in rats and 1908 in mice).
GENETIC VARIANTS IN microRNA-RELATED GENES IN
PSYCHIATRIC AND NEUROLOGIC DISORDERS
SINGLE NUCLEOTIDE POLYMORPHISMS IN microRNA MATURE
SEQUENCES OR PRECURSORS
The most considerable findings about an involvement of SNPs
located in miRNA mature sequences or precursors in neuropsy-
chiatric disorders come from studies on SCZ. Hansen et al. (2007)
identified an association between a SNP located in the brain-
expressed mir-206 (rs17578796) and the disease. Few years later,
an analysis of SNPs in miRNAs mapping on the X chromosome,
conducted on male SCZ subjects, led to the identification of 8
ultra-rare variants in 8 distinct miRNA genes (3 precursor and
5 mature miRNA sequences) in 4% of the analyzed patients (Feng
et al., 2009). In a Chinese population, a SNP located in pre-mir-
30e (ss178077483) was later detected to be associated to SCZ (Xu
et al., 2010a), and the same research group described an associa-
tion of this variant also with MD (Xu et al., 2010b). In a GWAS of
substantial size on SCZ, the strongest finding was with rs1625579,
a SNP located within an intron of the non-protein coding gene
AK094607, which contains the primary transcript for miR-137,
a known regulator of neuronal development (Ripke et al., 2011).
However, the polymorphism resides more than 8 kilobases away
from the pri-miR-137. In subsequent studies the same variant was
associated with specific SCZ/psychosis endophenotypes, charac-
terized by severe cognitive deficits and negative symptoms, rather
then with the disease itself (Cummings et al., 2013; Green et al.,
2013). Another recent study suggested a possible functional expla-
nation for this SNP, showing an association between the risk
genotype and reduced expression levels of miR-137 in the dorso-
lateral PFC of healthy subjects; interestingly, this corresponded to
increased levels of themiR-137 target gene TCF4, a SCZ candidate
gene (Guella et al., 2013).
Small evidence is available for MD; in addition to the above-
mentioned study on pre-mir-30e (ss178077483) (Xu et al.,
2010b), so far only another investigation has been conducted,
revealing an association between a SNP in pre-mir-182 and late
insomnia in MD patients, thus suggesting that this variant could
be involved in the alteration of circadian rhythms described in
depressed patients (Saus et al., 2010).
Finally, two SNPs, respectively located in mir-22 (rs6502892)
and mir-339 (rs11763020), were associated to panic disorder.
Interestingly, functional studies showed that mir-22 is a regulator
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of candidate genes for panic disorder (BDNF, HTR2C, MAOA
and RGS2), suggesting a possible contribution of its genetic vari-
ants in the development of this disease (Muiños-Gimeno et al.,
2011).
SINGLE NUCLEOTIDE POLYMORPHISMS IN microRNA TARGET GENES
Genetic variants in miRNA target genes, in particular in their
3′-UTR, are equally important as SNPs in miRNA mature
sequences or precursors, since they can alter the complemen-
tarity between mRNA and miRNA, therefore influencing their
binding.
Concerning psychiatric diseases, a SNP (rs3822674) in the
complexin 2 gene (CPLX2), associated with altered cogni-
tion in SCZ subjects, was described to affect miR-498 binding
and gene expression (Begemann et al., 2010). Interestingly, an
allelic variant of rs11122396 in the 3′-UTR of disrupted-in-
schizophrenia-1 (DISC-1) gene, which had been associated to
schizophrenia through a rare haplotype (Hennah et al., 2003),
has recently been brought to the forefront thanks to a func-
tional study showing that this variant disrupts miR-135b-5p
binding, leading to elevated DISC-1 levels (Rossi et al., 2013).
Finally, 3 other SNPs (rs17110432, rs11178988 and rs11178989)
in the 3′-UTR of TBC1D15 gene were reported as associated
to SCZ and predicted to affect miRNA binding (Liu et al.,
2012b).
Another significant association was detected between allelic
variants of rs1653625 in the purinergic receptor P2X gene
(P2RX7) and MD; this SNP resides in a putative miRNA target
site (Rahman et al., 2010). In patients affected by obsessive-
compulsive disorder (OCD), a SNP (rs28521337) located in a
functional target site for miR-485-3p, in the truncated isoform
of neurotrophin-3 receptor gene (NTRK3), was associated with
hoarding, a particular endophenotype of the disease (Muiños-
Gimeno et al., 2009).
Evidence in this field is available also for neurodegenerative
diseases: a study conducted on FTLD with TDP-43 inclusions
(FTLD-TDP) by Rademakers et al. (2008) unveiled a functional
effect for the high-risk allele of rs5848 in progranulin gene
(GRN), which promotes a more efficient binding of miR-659,
resulting in augmented translational inhibition of GRN. Similarly,
rs1050283 in the oxidized LDL receptor 1 gene (OLR1), which
acts as a risk factor for sporadic AD, was hypothesized to influ-
ence miR369-3p binding (Serpente et al., 2011). Moreover, other
previously known AD-associated genetic variants in the 3′-UTR
of APPwere empirically shown to influencemiRNA binding, both
by inhibiting (T117C, effect onmiR-147) or increasing it (A454G,
effect on miR-20a), and therefore inversely affecting APP levels
(Delay et al., 2011).
An association was also detected between PD and rs12720208
in the 3′-UTR of fibroblast growth factor 20 (FGF20) gene.
The risk allele was described to disrupt a binding site for
miR-433, increasing FGF20 levels in vitro and in vivo, and
the increase was correlated with α-synuclein overexpression,
which had previously been implicated in PD pathophysiol-
ogy (Wang et al., 2008b), though a later study failed to con-
firm the association of this SNP with PD (de Mena et al.,
2010).
SINGLE NUCLEOTIDE POLYMORPHISMS IN microRNA PROCESSING
GENES
Genetic variants affecting genes implicated in miRNA biogene-
sis and processing are extremely relevant, since they can exert
pleiotropic effects on a multitude of miRNAs.
So far, only two studies have inquired into this important
topic; the first one investigated the possible association between
MD and 3 SNPs located in 3 miRNA processing genes (DGCR8,
DICER, and GEMIN4). Variants of rs3757 in DGCR8 and
rs636832 in AGO1 were associated with an increased risk for this
disease (He et al., 2012). The second study evaluated 6 SNPs in 5
miRNA processing genes (DGCR8, DICER, GEMIN4, DROSHA,
and AGO1) in SCZ subjects. The same above-mentioned variant
in DGCR8 was found to be associated also with SCZ, together
with rs3742330 in DICER (Zhou et al., 2013). Interestingly, an
elevated expression of DGCR8 was observed in PFC of SCZ
patients (Santarelli et al., 2011); rs3757 is located in the 3′-UTR
of this gene, possibly affecting the regulation of its expres-
sion by miRNAs and resulting in an overall increase in miRNA
production.
Table 3 summarizes all the above-reported genetic studies in
psychiatric and neurologic disorders, with indication of samples
and main results.
CONCLUSIONS
The research on miRNA involvement in psychiatric and neu-
rologic disorders has grown up in the last years, supporting a
role of miRNAs in several neuropsychiatric conditions and sug-
gesting a possible usefulness of these small non-coding RNAs as
disease-related biomarkers.
However, the continuously growing number of annotated
miRNAs, as described in Figure 1, implies a major complex-
ity in the global interpretation of the current available results,
since many newly discovered miRNAs have not been suffi-
ciently studied yet. New investigations will be welcome to
clarify the role played by the already known miRNAs and
to identify new critical ones. Moreover, some technical issues
have to be resolved. A reliable and reproducible quantifica-
tion of miRNAs is essential to compare results arising from
different studies and, given that many experimental variables
can affect miRNA measurement, all the related technical pro-
cedures should be carefully optimized and standardized. Till
then, the transferability of these studies to the clinical prac-
tice will be inevitably limited. Finally, there is still a lack of
data about the origin of miRNAs in blood and also whether
they accurately reflect miRNA activity in the brain; further
studies to elucidate these aspects are needed (Kolshus et al.,
2013).
Concerning genetic studies on miRNA-related genes, we are
still in an embryonic stage, but the recent annotation of new
miRNA SNPs paves the way to a growing research in this field.
The study of miRNA CNVs is an even more unexplored area; new
investigations on these topics are strongly advisable to widen the
knowledge on the genetic bases of psychiatric and neurologic dis-
eases. Great help for these investigations is likely to come from the
new NGS technologies, allowing a faster and cheaper scan of the
whole genome than ever before.
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Table 3 | Genetic studies on microRNA-related genes in psychiatric and neurologic disorders.
Sample Main finding Reference
SNPs in miRNAs 840 SCZ vs. 1476 CTRL (Scandinavian) rs17578796 (in mir-206) associated with SCZ Hansen et al., 2007
193 SCZ vs. 191 CTRL (Caucasian, all
males)
Eight ultra-rare variants on X chromosome identified in 4%
of SCZ patients:
32 A>G in pre-mir-18b, 8 C>T in pre-mir-505, 13 C>G in
pre-mir-502, 11 G>A in let-7f-2, 7 C>T in mir-188-3p, 8 G>A
in mir-325-3p, 15 C>T in mir-660, 13 C>T in mir-509-3p
Feng et al., 2009
456 SCZ vs. 453 CTRL (Chinese) ss178077483 (in pre-mir-30e) associated with SCZ Xu et al., 2010a
Discovery stage: 9394 SCZ vs. 12462
CTRL; replication stage: 8442 SCZ vs.
21397 CTRL (European-ancestry)
rs1625579 (in a putative primary transcript for mir-137)
associated with SCZ
Ripke et al., 2011
617 SCZ vs. 764 CTRL (Australian) rs1625579 (in a putative primary transcript for mir-137)
associated with a specific SCZ phenotype
Green et al., 2013
821 SCZ/BD/SCHIZOAFFECTIVE vs.
171 CTRL (Irish)
rs1625579 (in a putative primary transcript for mir-137)
associated with a specific psychosis phenotype
Cummings et al., 2013
1088 MD vs. 1102 CTRL (Chinese) ss178077483 (in pre-mir-30e) associated with MD Xu et al., 2010b
359 MD vs. 341 CTRL (Spanish) rs76481776 (in pre-mir-182) associated with late insomnia
MD
Saus et al., 2010
200 panic disorder vs. 340 CTRL
(Spanish)
rs6502892 (in mir-22) and rs11763020 (in mir-339)
associated with panic disorder
Muiños-Gimeno et al.,
2011
SNPs in miRNA
target genes
1071 SCZ (Caucasian) rs3822674 (in CPLX2 gene) associated with altered
cognition in SCZ subjects, affecting miR-498 binding and
gene expression
Begemann et al., 2010
607 SCZ vs. 1128 CTRL (Finnish) rs11122396 in DISC-1 gene associated to SCZ through a
rare haplotype
Hennah et al., 2003
746 SCZ vs. 1599 CTRL (Chinese) rs17110432, rs11178988 and rs11178989) in TBC1D15 gene
associated to SCZ, possibly affecting miRNA binding
Liu et al., 2012b
171 MD+BD vs. 178 CTRL (Hungarian) rs1653625 (in a putative miRNA-target site in P2RX7 gene)
associated with MD
Rahman et al., 2010
153 OCD (Spanish) rs28521337 (in a target site for miR-485-3p in the truncated
isoform of NTRK3 gene) associated with hoarding
phenotype of OCD
Muiños-Gimeno et al.,
2009
59 FTLD vs. 433 CTRL (ethnicity not
specified)
rs5848 (in GRN gene) associated with FTLD, enhancing
miR-659 binding and translational inhibition of GRN
Rademakers et al., 2008
453 AD vs. 393 CTRL (Italian) rs1050283 (in OLR1 gene) associated with AD, possibly
influencing miR-369-3p binding
Serpente et al., 2011
1089 PD vs. 1165 CTRL (ethnicity not
specified)
rs12720208 (in FGF20 gene) associated with PD, disrupting
miR-433 binding and increasing FGF20 levels
Wang et al., 2008b
SNPs in miRNA
processing
genes
252 SCZ vs. 256 CTRL (Chinese) rs3757 (in DGCR8 gene) and rs3742330 (in DICER gene)
associated with SCZ
Zhou et al., 2013
314 MD vs. 252 CTRL (Chinese) rs3757 (in DGCR8 gene) and rs636832 (in AGO1 gene)
associated with MD
He et al., 2012
BD, bipolar disorder patients; CTRL, healthy controls; FTLD, frontotemporal lobar degeneration; MD, major depression patients; OCD, obsessive-compulsive disorder
patients; SCZ, schizophrenia patients.
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In general, the scientific community has great expectations
for the use of miRNA measures and genetic data as non-
invasive biomarkers for the diagnosis, prognosis, and therapeutic
appraisal of many illnesses. The fact that differential expression
levels of peripheral miRNAs have been associated with several
disease processes and to similarmodifications in brain tissues sug-
gests the potential for using them as a new generation of biomark-
ers in neuropsychiatric conditions and opens new avenues for the
treatment of these disorders.
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